Abstract 174P
Background
Hepatocellular carcinoma (HCC) patients with major vascular invasion (MVI) were generally recommend systemic treatment by guidelines, while some data showed R0 resection can improve survival than local treatment. Conversion therapy using immune checkpoint inhibitors may benefit these patients in the context of cancer immunotherapy. Here we report a prospective real-world study of PD-1 inhibitors in combination with tyrosine kinase inhibitors (TKIs) as a conversion therapy for HCC with MVI.
Methods
Briefly, the main inclusion criteria of the study (ChiCTR1900023914) was: Aged 18 to 75 years HCC patients diagnosed pathologically and/or radiologically, with at least one measurable lesion (mRECIST) and MVI. The criteria for Successful Conversion: 1. Child-Pugh score < 7. 2. ECOG PS score ≤1. 3. No extrahepatic lesion. 4. Intact vascular structure of the reserved liver and sufficient FLR.
Results
70 Patients were screened, and 39 patients enrolled in the study by May 20, 2020. Among them 35 patient accepted the combination therapy (Primary HCC n=31, Recurrence after local treatment n=4), in which 30 patients with PVTT, 2 with venous tumor thrombi and 3 with both. A total of 33 patients were assessable. The response evaluation according to mRECIST standard was in table below. Successful conversion rate based on radiology was 42.4% (14/33). Table: 174P
Summary of response evaluation and conversion rate
Best objective response, n | Total, n | ||||
CR n=5 | PR n=10 | SD n=12 | PD n=6 | 33 | |
Successful Conversion, n | 5 | 7 | 1 | 1 | 14 |
Reasons for not conversion | Inadequate FLR n=2, Poor CTP n=1 | Inadequate FLR n=11 | Inadequate FLR n=5 | ||
Patients underwent subsequent surgery, n | 4 | 3 | 1 | 1 | 9 |
Pathological evaluation of response | pPR: 1/4 | pPD: 2/3 | pSD | pPD |
The subsequent salvage surgery was all en-bloc R0 resection of both tumor and PVTT. No complications beyond Clavien-Dindo level III or postoperative mortality were observed. The median follow-up time was 7.2 months. The median relapse free survival and median overall survival was 3.9 months and 6.5 months respectively. Patients with pPD had a worse prognosis.
Conclusions
The combination therapy of PD-1 inhibitors and TKIs can be reviewed as a reasonable and promising conversion therapy option for advanced HCC with safety and effectiveness. Furthermore, pathology can confirm the response evaluation and guide subsequent treatment more precisely.
Clinical trial identification
ChiCTR1900023914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session